Run by the daughter of a renowned genetic oncologist, CancerIQ is expanding and raising money as it rolls out its testing management and clinical decision support technology.
The test, which uses lateral flow immunochromatographic technology, demonstrated high accuracy in a recent study and is being planned for a submission to the FDA.
